Loading…
← CockpitCompetitor Analysis › 301520.SZ Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class AOpen in the cockpit ↗

Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A301520.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Anhui-based pharmaceutical technology company; specific product line not established from available knowledge.

Momentum leader 91
Mkt cap
$684M
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$91.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-7.6 pp
WACC 6.8%
Hurdle
+30 pp
Req g minus delivered
Close · CNYCN¥51.09
1D-0.6%
1W-16.2%
1M-11.5%
3M-42.4%
6M+73.6%
YTD+80.0%
1Y+68.2%
ATR %11.0%
52w lowhigh42.5% off high

What Anhui Wanbang Pharmaceutical Technology does

Anhui-based pharmaceutical technology company; specific product line not established from available knowledge.

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals

Moat: none

Headquarters: Anhui, China · Employees: 376

Anhui Wanbang Pharmaceutical Technology at a glance

Size Anhui Wanbang Pharmaceutical Technology (301520.SZ) is a China Health Care company (Biotechnology) with a market value of $684M, the 2939th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥51.09 on 18 Nov 2026.

Performance Over six months the shares gained 73.6%, against -23.5% for the median peer and -20.0% for the China market (cap-weighted) — 3rd highest of 19 in its peer set.

Growth Revenue fell 15.3% over the last twelve months (peer median +18.4%); the operating margin is -8.2% (peer median -99.9%).

Valuation It trades at 14.7× enterprise value to sales against a peer median of 6.9× (6th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 45% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +30 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.6 points below its cost of capital (6.8% WACC).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026301520.SZ 172Peer median 76
Six months, rebased to 100: Anhui Wanbang Pharmaceutical Technology against the median of its 20 peers (local-currency closes).

Anhui Wanbang Pharmaceutical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥249MCN¥274MCN¥378MCN¥341MCN¥260M
Revenue growth—-27%+11%+31%—
Gross profitCN¥62.1MCN¥61.3MCN¥139MCN¥160MCN¥128M
EBITDAn/aCN¥20.3MCN¥68.8MCN¥115MCN¥104M
Net incomeCN¥3.90MCN¥36.4MCN¥85.5MCN¥108MCN¥98.7M
Free cash flowCN¥21.2M-CN¥9.63MCN¥26.2M-CN¥11.7MCN¥24.8M
Capital expenditureCN¥3.79MCN¥19.2MCN¥41.8MCN¥86.0MCN¥50.7M
Total debtCN¥1.96MCN¥4.29MCN¥1.60MCN¥1.00MCN¥29,884

Quarterly statements and history in the cockpit →

Anhui Wanbang Pharmaceutical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%KURAPRME77299966SLDB688221ATTOGERNJANXAURA9887301520.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Anhui Wanbang Pharmaceutical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%0×5,000×10,000×KURAPRME688197IVA301520.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Anhui Wanbang Pharmaceutical Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688221301333002038603387301520.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Anhui Wanbang Pharmaceutical Technology is the large dot.

Anhui Wanbang Pharmaceutical Technology competitors and peer comparison

How Anhui Wanbang Pharmaceutical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anhui Wanbang Pharmaceutical Technology against its 20 peers (data as of 18 Nov 2026)
Measure301520.SZPeer medianRank in peer set
1-month return-11.5%-7.0%8th lowest of 21
6-month return+73.6%-23.5%3rd highest of 19
Distance from 52-week high-42.5%-47.7%6th highest of 21
Revenue growth (TTM)-15.3%+18.4%4th lowest of 15
Operating margin-8.2%-99.9%4th highest of 17
EV / Sales14.7×6.9×6th most expensive of 16
Growth the price implies (Req g, 7 yrs)44.8%4.2%most demanding of 5
Growth delivered (Del g)+14.7%+5.3%2nd highest of 5
Hurdle (Req g minus delivered)+30.1 pp+1.4 ppmost demanding of 5
ROIC minus cost of capital-7.6 pp-15.9 pp4th highest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a

Questions

Which companies are Anhui Wanbang Pharmaceutical Technology's closest peers?
The cockpit's peer set: Kura Oncology (KURA), Prime Medicine (PRME), Steminent Biotherapeutics (7729.TWO), Alphamab Oncology (9966.HK), Solid Biosciences (SLDB), Frontier Biotechnologies (688221.SS), Attovia Therapeutics (ATTO), Shaanxi Micot Pharmaceutical Technology (2335.HK).
Is Anhui Wanbang Pharmaceutical Technology expensive compared with its peers?
On ev / sales it trades at 14.7× against a peer median of 6.9×, 6th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 45% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +30 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Anhui Wanbang Pharmaceutical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned +73.6% against -23.5% for the median peer; over one year +68.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.